Brought to you by 
Teva acquires movement disorder-focused Auspex for $3.2bn
10 Sep 2020
Executive Summary
True to its words in late 2014 that it would be refocusing efforts toward neurological disease, Teva Pharmaceutical Industries Ltd. bought publicly traded Auspex Pharmaceuticals Inc. (rare diseases, specifically movement disorders) for $3.2bn ($101 per share, a 32% premium).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva acquires movement disorder-focused Auspex for $3.2bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice